Biotechnology News and Research

RSS

Lauren Sciences, BGN Technologies sign licensing agreement for V-Smart- drug delivery technology

BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev (BGU), has signed a licensing agreement for its V-Smart- drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

11 Apr 2012

Amgen enters agreement to acquire KAI Pharmaceuticals

Amgen and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.

11 Apr 2012

Simulations Plus second quarter net sales increase 6.4% to $2.789M

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its second quarter of fiscal year 2012 ended February 29, 2012.

11 Apr 2012

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest is seeking marketing approval in Canada for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

10 Apr 2012

Delcath, NKI-AVL enter initial launch and training agreement for CHEMOSAT system

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement with the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam, The Netherlands.

10 Apr 2012

Study: Body and head lice are the same species

A new study offers compelling genetic evidence that head and body lice are the same species. The finding is of special interest because body lice can transmit deadly bacterial diseases, while head lice do not.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

RegeneRx wins four patents in Israel, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel.

10 Apr 2012

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Nuron Biotech, Inc. today announced it has licensed from VITRUVIAN BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer's disease (AD).

9 Apr 2012

FDA grants IDE approval for Arteriocyte's Magellan MAR01 Phase I Compartment Syndrome clinical trial

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Compartment Syndrome.

7 Apr 2012

NIMH honors SUNY Downstate professor with MERIT award

Todd C. Sacktor, M.D., distinguished professor of physiology and pharmacology and of neurology at SUNY Downstate Medical Center, has received a MERIT (Method to Extend Research in Time) award from the National Institute of Mental Health (NIMH) for his research on memory.

7 Apr 2012

Presage Biosciences enters cancer research agreement with Millennium

Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company.

7 Apr 2012

Teva's ANDA for Provigil entitled to 180-day exclusivity

Teva Pharmaceutical Industries Ltd. announces that the FDA has decided that its wholly owned subsidiary, Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil (modafinil) and therefore Teva's ANDA alone is entitled to 180-day exclusivity.

6 Apr 2012

Poultry producers still use FDA-banned antibiotics

In a joint study, researchers at the Johns Hopkins Bloomberg School of Public Health and Arizona State University found evidence suggesting that a class of antibiotics previously banned by the U.S. government for poultry production is still in use. Results of the study were published March 21 in Environmental Science & Technology.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

Advaxis, Karolinska Institutet enter collaboration to develop cat allergy vaccine

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a research collaboration with Professor Marianne van Hage, research group leader and Head of the Clinical Immunology and Allergy Unit and Vice Head of the Department of Medicine at Karolinska Institutet in Stockholm, Sweden.

6 Apr 2012

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

Label-Free Technologies Conference to be held in Amsterdam

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the Label-Free Technologies Conference to be held in Amsterdam, the Netherlands, 1-3 November 2012.

6 Apr 2012

Only few women consume aspirin to reduce risk of heart disease

Heart disease is the leading cause of death among women, and evidence-based national guidelines promote the use of daily aspirin for women at increased risk for cardiovascular disease. However, less than half of the women who could benefit from aspirin are taking it, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc.

5 Apr 2012

Applied BioCode receives U.S. patent titled, ‘Light Transmitted Assay Beads’

Applied BioCode, Inc. today announced that the United States Patent and Trademark Office has issued US Patent #8,148,139 "Light Transmitted Assay Beads," describing the method of use and manufacturing of its Barcoded Magnetic Beads (BMB) products.

5 Apr 2012